In the United States, a common practice in the management of ductal carcinoma in situ (DCIS) costs an estimated $35 million a year, but is unnecessary, according to a new study. Automatically testing ...
For patients with the most common type of noninvasive breast cancer, routine testing for estrogen and progesterone receptors in tissue taken at the first "needle" biopsy is both unnecessary and ...
Guardant Health, Inc. stock outlook: strong oncology growth and liquid biopsy adoption drive revenue. Click for this updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results